Moreover, it was already evidenced the role of PLCβ1 as possible molecular marker able to define specific and personal therapeutic strategies in other tumor patients, as myelodysplastic syndromes (MDS) patients [29, 30]. Here, PLCB1 is linked to myelodysplastic syndrome.